Product Name: DRAK2 antibody
Applications: ICC/IF, WB
Predicted Target Size:
Positive Controls: Wholecell lysate from Jurkat cells An approximately 45 kDa band can be detected.
Form Supplied:
Concentration: 0.5 mg/ml (Please refer to the vial label for the specific concentration)
Purification: IgG fraction
Full Name: serine/threonine kinase 17b
Background: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).
Synonyms: 9262, DRAK2, STK17B, 604727, O94768
Cellular Localization: Nuclear
CAS NO: 120964-45-6
Product: LUF6000
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: Synthetic peptide, corresponding to amino acids 351-365 of Human DRAK2.
Antigen Species: Human
Species Reactivity: Human
Conjugation: Unconjugated
Storage Buffer: PBS with 0.02% sodium azide
Storage Instruction: Keep as concentrated solution, aliquot and store at 4°C.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity: None to DAP or ZIP kinases. The approximately 70 kDa band visible on WesGTX11950tern blots is probably non-related to DRAK2 although it is peptide blockable with GTX28454.
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/15717301?dopt=Abstract
